Related Experiment Video
Updated: Jul 11, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Deferasirox: the new oral iron chelator
A P Dubey1, S Sudha, Ankit Parakh
1Department of Pediatrics, Maulana Azad Medical College, New Delhi 110 002, India. apdubey52@rediffmail.com
Abstract:
Deferasirox is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children above 2 years. Phase II/III trials have demonstrated similar efficacy to desferrioxamine and better chelation efficiency. Adverse events were minor and growth remained unaffected. Data on cardiac iron chelation is limited although some studies have shown it comparable to deferiprone. The benefit to risk profile of deferasirox is favorable. This promising new drug might decrease the burden of subcutaneous or intravenous infusion improving compliance and hence the life expectation in thalassemic patients.
Related Concept Videos
The Early Endosome: Endocytosis of Transferrin
Antiprotozoal Agents
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Anthelminthic Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

